Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gonadotropin alone versus gonadotropin plus clomiphene in poor ovarian responders undergoing ART
IRCT20250503065568N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of clomiphene, human menopausal gonadotrophin, cetrorelix and human chorionic gonadotropin in infertility and poor ovarian response (POR) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Number of oocytes retrieved. Started Jul 2025; status: completed.
02
Drugs
clomiphenehuman menopausal gonadotrophincetrorelixhuman chorionic gonadotropin
03
Conditions
infertilitypoor ovarian response (POR)
Beyond the preview
Go deeper on IRCT20250503065568N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250503065568N1.